Dublin, April 09, 2021 (GLOBE NEWSWIRE) -- The "Global Precision Psychiatry Market: Focus on Product Type, Biomarker, Sample, Technology, Applications, End Users, Country Data (15 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global market for precision psychiatry is predicted to grow at a CAGR of 17.26% over the forecast period of 2021-2026. The market is driven by certain factors, which include decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden, that are fuelling the growth of the global precision psychiatry market.
The market is favored by the developments in the field of molecular diagnostics, which are used for the diagnosis and assessment of psychiatric disorders. Currently, the precision psychiatry industry is witnessing an upsurge due to the decreasing cost of sequencing, increasing adoption of inorganic growth strategies, and global increase in mental health burden. Additionally, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis related to the onset and manifestation of psychiatric disorders are some of the critical factors that are expected to bolster the market growth.
Furthermore, biotechnology companies are focusing on the development of robust precision psychiatry solutions for a wide range of applications to support clinicians in conducting an in-depth molecular analysis.
Within the research report, the market is segmented on the basis of product type, biomarker, sample, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Decreasing Cost of Sequencing
Increasing Adoption of Inorganic Growth Strategies
Global Increase in Mental Health Burden
Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry
Lack of Awareness for Precision Psychiatry Diagnostics
Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies
Massive Scope for Adoption of NGS-Based Genetic Tests in Emerging Markets
Key Companies Profiled
Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, ARUP Laboratories, Invitae Corporation, OPKO Health, Inc., Laboratory Corporation of America Holdings, Centogene N.V., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Konica Minolta, Inc., Fulgent Genetics, PreventionGenetics
Key Questions Answered in this Report:
How is precision psychiatry revolutionizing the field of mental health diagnostics?
What are the major market drivers, challenges, and opportunities in the global precision psychiatry market?
What are the underlying structures resulting in the emerging trends within the global precision psychiatry market?
How is the COVID-19 pandemic impacting the global precision psychiatry landscape?
What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?
What are the key regulatory implications in developed and developing regions pertaining to precision psychiatry?
What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
How is each segment of the market expected to grow during the forecast period from 2021 to 2026, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
Product Type (Products and Services)
Sample (Blood-Based and Non-Blood-Based)
Biomarker (Genetic Biomarkers and Protein)
Technology (Sequencing, PCR, Microarray, Immunoassay, LC/MS, and Others)
Application (Parkinson's Disease, Autism, Alzheimer's Disease, Depression, Schizophrenia, Bipolar Disorder, and Others)
End User (Hospitals and Diagnostic Laboratories, Academic and Research Institutions, and Others)
Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
What are the growth opportunities for the companies in the region of their operation?
Who are the leading players with significant offerings in the global precision psychiatry market?
Which companies are anticipated to be highly disruptive in the future, and why?
What are the current unmet needs that are being faced in the global precision psychiatry market?
Key Topics Covered:
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Precision Psychiatry Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 Market Overview
4.1 Market Definition
4.2 Market Footprint and Growth Potential
4.3 Future Potential
4.4 COVID-19 Impact: Global Precision Psychiatry Market
5 Market Dynamics
5.2 Market Drivers
5.2.1 Decreasing Cost of Sequencing
5.2.2 Increasing Adoption of Inorganic Growth Strategies in the Market
5.2.3 Global Increase in Mental Health Burden
5.3 Market Restraints
5.3.1 Lack of Established Regulatory Policies for Precision Diagnostics in the Field of Precision Psychiatry
5.3.2 Lack of Awareness for Precision Psychiatry Diagnostics
5.4 Market Opportunities
5.4.1 Increased Use of Precision Diagnostics for Drug Development by Pharmaceutical and Companion Diagnostics Companies
5.4.2 Massive Scope for Adoption of NGS-based Genetic Tests in Emerging Markets
6 Industry Insights
6.2 Legal Requirements and Framework in the U.S.
6.2.1 FDA Regulation
6.2.2 CMS Regulation
6.3 Legal Requirements and Framework in Europe
6.4 Legal Requirements and Framework in Asia-Pacific
6.4.3 South Korea
7 Competitive Landscape
7.1 Product Launches
7.2 Product Approvals and Designations
7.3 Synergistic Activities
7.6 Market Share Analysis, by Company, 2019-2020
7.7 Growth Share Analysis
7.7.1 Growth Share Analysis (by Company)
8 Global Precision Psychiatry Market (by Product Type)
9 Global Precision Psychiatry Market (by Biomarker Type)
9.2 Genetic Biomarkers
9.2.1 Genetic Biomarkers (by Application)
18.104.22.168 Parkinson's Disease
22.214.171.124 Alzheimer's Disease
126.96.36.199 Bipolar Disorder
188.8.131.52 Other Applications
9.3 Protein Biomarkers
9.3.1 Protein Biomarkers (by Application)
184.108.40.206 Parkinson's Disease
220.127.116.11 Alzheimer's Disease
18.104.22.168 Bipolar Disorder
22.214.171.124 Other Applications
10 Global Precision Psychiatry Market (by Sample)
10.3.3 Cerebral Spinal Fluid (CSF)
11 Global Precision Psychiatry Market (by Technology)
11.2.1 Next-Generation Sequencing (NGS)
11.2.2 Sanger Sequencing
11.3 Polymerase Chain Reaction (PCR)
11.3.1 Real-Time Polymerase Chain Reaction (RT-PCR)
11.3.2 Digital Polymerase Chain Reaction (dPCR)
11.6 Liquid Chromatography-Mass Spectrometry (LC-MS)
11.7 Other Technologies
12 Global Precision Psychiatry Market (by Application)
12.2 Alzheimer's Disease
12.2.1 Global Precision Psychiatry Market for Alzheimer's Disease (by Technology)
12.3 Parkinson's Disease
12.3.1 Global Precision Psychiatry Market for Parkinson's Disease (by Technology)
12.4.1 Global Precision Psychiatry Market for Autism (by Technology)
12.5.1 Global Precision Psychiatry Market for Depression (by Technology)
12.6.1 Global Precision Psychiatry Market for Schizophrenia (by Technology)
12.7 Bipolar Disorder
12.7.1 Global Precision Psychiatry Market for Bipolar Disorder (by Technology)
12.8 Other Applications
13 Global Precision Psychiatry Market (by End User)
13.2 Hospitals and Diagnostic Laboratories
13.3 Academic and Research Institutions
13.4 Other End Users
14 Global Precision Psychiatry Market (by Region)
14.2 North America
14.4.3 South Korea
14.5 Latin America
14.5.3 Rest-of-Latin America
14.6 Rest-of-the-World (RoW)
15 Company Profiles
15.2 Illumina, Inc.
15.2.1 Company Overview
15.2.2 Role of Illumina, Inc. in the Global Precision Psychiatry Market
15.2.4 Key Insights About Financial Health of the Company
15.2.5 SWOT Analysis
15.3 F. Hoffmann-La Roche Ltd.
15.3.1 Company Overview
15.3.2 Role of F. Hoffmann-La Roche Ltd in the Global Precision Psychiatry Market
15.3.4 Key Insights About Financial Health of the Company
15.3.5 SWOT Analysis
15.4 Bio-Rad Laboratories, Inc.
15.4.1 Company Overview
15.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Precision Psychiatry Market
15.4.4 Key Insights About Financial Health of the Company
15.4.5 SWOT Analysis
15.5 QIAGEN N.V.
15.5.1 Company Overview
15.5.2 Role of QIAGEN N.V. in the Global Precision Psychiatry Market
15.5.4 Key Insights about Financial Health of the Company
15.5.5 SWOT Analysis
15.6 Quest Diagnostics Incorporated
15.6.1 Company Overview
15.6.2 Role of Quest Diagnostics Incorporated in the Global Precision Psychiatry Market
15.6.4 SWOT Analysis
15.7 ARUP Laboratories
15.7.1 Company Overview
15.7.2 Role of ARUP Laboratories in the Global Precision Psychiatry Market
15.7.3 SWOT Analysis
15.8 Invitae Corporation
15.8.1 Company Overview
15.8.2 Role of Invitae Corporation, Inc. in the Global Precision Psychiatry Market
15.8.4 Key Insights About Financial Health of the Company
15.8.5 SWOT Analysis
15.9 OPKO Health, Inc.
15.9.1 Company Overview
15.9.2 Role of OPKO Health, Inc. in the Global Precision Psychiatry Market
15.9.4 Key Insights About Financial Health of the Company
15.9.5 SWOT Analysis
15.1 Laboratory Corporation of America Holdings
15.10.1 Company Overview
15.10.2 Role of Laboratory Corporation of America Holdings in the Global Precision Psychiatry Market
15.10.4 SWOT Analysis
15.11 CENTOGENE N.V.
15.11.1 Company Overview
15.11.2 Role of CENTOGENE N.V. in Precision Psychiatry Market
15.11.4 Key Insights About Financial Health of the Company
15.11.5 SWOT Analysis
15.12 Thermo Fisher Scientific Inc.
15.12.1 Company Overview
15.12.2 Role of Thermo Fisher Scientific Inc. in Global Precision Psychiatry Market
15.12.4 Key Insights About Financial Health of the Company
15.12.5 SWOT Analysis
15.13 Myriad Genetics, Inc.
15.13.1 Company Overview
15.13.2 Role of Myriad Genetics, Inc. in the Global Precision Psychiatry Market
15.13.4 Key Insights About Financial Health of the Company
15.13.5 SWOT Analysis
15.14 Konica Minolta, Inc.
15.14.1 Company Overview
15.14.2 Role of Konica Minolta, Inc. in the Global Precision Psychiatry Market
15.14.4 Key Insights About Financial Health of the Company
15.14.5 SWOT Analysis
15.15 Fulgent Genetics
15.15.1 Company Overview
15.15.2 Role of Fulgent Genetics in the Global Precision Psychiatry Market
15.15.4 Key Insights About Financial Health of the Company
15.15.5 SWOT Analysis
15.16.1 Company Overview
15.16.2 Role of the PreventionGenetics in the Global Precision Psychiatry Market
15.16.3 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/s3182e
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900